BIOMIND LABS INC - BMNDF STOCK NEWS

Biomind Labs Inc. has secured a Controlled Substances License and initiated an eight-month project to develop novel hydrogel-forming microneedle arrays for transdermal delivery of psychedelic compounds like DMT and mescaline. Partnering with Queen’s University of Belfast, the project aims to enhance drug delivery efficacy while potentially broadening the market for treatments of inflammation, pain, and neurodegenerative disorders. This collaboration could strengthen Biomind's intellectual property portfolio and innovate drug delivery systems.

Biomind Labs has finalized the dose administration for 30 subjects in its Phase II trial of BMND01, aimed at treating Treatment-Resistant Depression. Results are expected in October 2022. This clinical trial explores an inhaled DMT formulation, intending to enhance rapid delivery into the bloodstream. Treatment-resistant depression affects 10-30% of patients, presenting significant healthcare challenges. Biomind Labs focuses on developing pharmaceutical formulations of psychedelics to offer modern treatments for various neurological and psychiatric conditions.

Biomind Labs Inc. has appointed Dr. Thomas Laughren as Medical Advisor for Clinical Trials. Dr. Laughren, former FDA Director for the Division of Psychiatry Products, brings extensive regulatory experience to the company. This addition aligns with Biomind's plans to enter the registration process for drug candidates with the FDA and EMA. The company is focused on developing psychedelic-based pharmaceuticals targeting conditions like depression and Alzheimer's, having submitted 20 patent applications to protect its innovations.

Biomind Labs Inc. announced the approval of a third Phase II clinical trial for its BMND08 candidate, which utilizes 5-MeO-DMT to treat depression and anxiety in patients with Alzheimer’s-type cognitive impairment. The trial, approved by the Argentinian Institutional Review Board, aims to explore innovative treatments addressing the urgent need for effective solutions in managing Alzheimer’s symptoms, including agitation and anxiety. CEO Alejandro Antalich emphasized the significance of this development in combining fast-acting psychedelic molecules with existing clinical practices.

Biomind Labs announced that CEO Alejandro Antalich will debate at the PSYCH Symposium in London on May 11, 2022. The symposium focuses on the potential of psychedelic healthcare. Antalich highlighted the importance of this discussion and expressed respect for UK Prime Minister Boris Johnson's consideration of psychedelic drug legalization. The company aims to develop pharmaceuticals using psychedelic molecules to address mental health disorders, emphasizing the need for further research to aid nearly one billion affected individuals.

Biomind Labs Inc. has announced the start of dose administration in a Phase I/IIa clinical trial for BMND01, a novel inhaled DMT formulation aimed at treating treatment-resistant depression. This unique trial, led by Dr. Dráulio Araújo, is the first of its kind globally to test an inhaled DMT drug and is being conducted at the University Hospital Onofre Lopes. The study will eventually include psychedelic-naïve patients. Initial dosing in health volunteers is expected to complete within four months.

Biomind Labs Inc. (OTC: BMNDF) announced its participation in the PSYCH Symposium on May 11, 2022, at The National Gallery in London. CEO Alejandro Antalich emphasized the event's significance in the psychedelic industry, aiming to foster discussions on mental health treatment advancements. The UK is becoming a leader in psychedelic research, advocating for greater collaboration and regulatory analysis. Biomind Labs focuses on developing novel pharmaceutical formulations of psychedelic compounds to address psychiatric and neurological disorders, promoting accessible treatments for patients.

Biomind Labs Inc., a leading biotech firm focused on endogenous tryptamines for mental health, announces CEO Alejandro Antalich and Dr. Dráulio Barros de Araújo will present at the Benzinga Psychedelics Capital Conference on April 19, 2022, in Miami. Attendees will gain insights into Biomind's diverse portfolio, including the BMND06 clinical trial and advances in DMT research, targeting depression. The Company aims to develop affordable psychedelic treatments through innovative drug delivery systems.

Biomind Labs Inc. has announced the launch of a commercial clinical trial for its proprietary drug candidate, BMND06, which is based on mescaline, a psychedelic molecule. This trial is a significant step towards the registration of its product, Triptax® M, with the FDA and the European Medicines Agency. The trial aims to address inflammation linked to depression, showcasing a strategic expansion beyond the company's previous focus on DMT and 5-MeO-DMT. The trials will be conducted in partnership with the esteemed Albert Einstein Hospital, adhering to high ethical and quality standards.